港股创新药板块盘中探底回升，港股创新药ETF（159567）逆势涨近1%，连续8个月获资金净流入

Core Viewpoint - The Hong Kong stock market is experiencing fluctuations, with the Hang Seng Index dropping over 1%. However, the innovative drug sector is showing resilience, with the Hong Kong Innovative Drug ETF (159567) rising nearly 1% during the session [1]. Industry Summary - The innovative drug sector is expected to benefit from supportive policies, allowing newly listed products to quickly realize commercial value. The implementation of national policies encouraging innovative drugs is anticipated to increase the market share of domestic innovative drugs in hospitals [1]. - The mid-year performance reports indicate a recovery in earnings for sub-sectors such as innovative drugs, CXO, and biopharmaceuticals within the pharmaceutical industry [1]. - The sector is supported by three key logics: "innovation upgrade, profit inflection point, and normalization of overseas business development," which are expected to sustain future market performance [1]. Company Summary - The Hong Kong Innovative Drug ETF (159567) has shown impressive performance this year, with a cumulative increase of over 95% and continuous net inflows for eight consecutive months, reaching a record high of over 8.1 billion shares [1]. - The ETF tracks the Guotai Junan Hong Kong Stock Connect Innovative Drug Index, reflecting the operational characteristics of listed companies in the innovative drug sector within the Hong Kong Stock Connect framework [1]. - Investors can also access the Hong Kong Innovative Drug ETF through linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward opportunities in the innovative drug sector [1].